CMC Considerations For CRISPR And Next-Gen Technologies, Including Elevatebio's LETI-101 As A Case Study

By Dr. April Sena, VP of Technical Operations

As CRISPR technology has expanded beyond nuclease editing into base editing, RT editing, and epigenome modification, the CMC considerations have grown correspondingly more complex. Each modality shares a common ribonucleoprotein foundation, yet each introduces its own manufacturing constraints: next-generation editors with added functional domains may not express well in microbial fermentation systems, guide RNAs for RT editing are substantially longer, and in vivo applications require nucleotide modifications that affect both stability and purity.

Dr. April Sena, VP of Technical Operations, examines these platform-level CMC considerations alongside a pre-clinical case study in Huntington's disease. The case study illustrates how decisions made during vector construct optimization affected not only full capsid yield but also editing selectivity in patient-derived cells, and how early regulatory engagement with MHRA shaped the comparability, potency, and impurity strategies required for clinical advancement.

Explore further to see how these technical and regulatory considerations intersect in practice.